Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
Journal: Endocrine-related cancer
Published: November 17, 2025
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
Published: October 22, 2025
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Journal: The New England journal of medicine
Published: September 16, 2024
Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy.
Journal: Frontiers in oncology
Published: May 14, 2024
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.
Journal: Endocrine-related cancer
Published: December 11, 2023
Resection Prolongs Overall Survival for Nonmetastatic Midgut Small Bowel Neuroendocrine Tumors: A National Cancer Data Base Study.
Journal: Pancreas
Published: April 11, 2022
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).
Journal: Endocrine-related cancer
Published: March 21, 2022
The Mount Sinai Clinical Pathway for the Diagnosis and Management of Hypercortisolism due to Ectopic ACTH Syndrome.
Journal: Journal of the Endocrine Society
Published: November 18, 2021
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 25, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 10, 2020
Last Updated: 09/26/2026